Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
benralizumab low affinity immunoglobulin gamma fc region receptor iii-a biotech NA drugbank Maintenance[MeSHID:D008283]
Serum[MeSHID:D044967]
Eosinophilia[MeSHID:D004802]
Asthma[MeSHID:D001249]
Lung[MeSHID:D008168]
Cell Differentiation process[MeSHID:D002454]
Continuance of life[MeSHID:D013534]
Phenotype[MeSHID:D010641]
eosinophil[MeSHID:D004804]
Inspiration function[MeSHID:D001239]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Chronic Obstructive Airway Disease[MeSHID:D029424]		 NA approved,investigational binding
benralizumab interleukin-5 NA Successful target TTD , DGIDB Maintenance[MeSHID:D008283]
Serum[MeSHID:D044967]
Eosinophilia[MeSHID:D004802]
Asthma[MeSHID:D001249]
Lung[MeSHID:D008168]
Cell Differentiation process[MeSHID:D002454]
Continuance of life[MeSHID:D013534]
Phenotype[MeSHID:D010641]
eosinophil[MeSHID:D004804]
Inspiration function[MeSHID:D001239]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Chronic Obstructive Airway Disease[MeSHID:D029424]		 9.09 approved unknown
benralizumab interleukin-5 receptor subunit alpha biotech NA drugbank , DGIDB Maintenance[MeSHID:D008283]
Serum[MeSHID:D044967]
Eosinophilia[MeSHID:D004802]
Asthma[MeSHID:D001249]
Lung[MeSHID:D008168]
Cell Differentiation process[MeSHID:D002454]
Continuance of life[MeSHID:D013534]
Phenotype[MeSHID:D010641]
eosinophil[MeSHID:D004804]
Inspiration function[MeSHID:D001239]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Chronic Obstructive Airway Disease[MeSHID:D029424]		 222.78 approved,investigational antibody,inhibitor
benralizumab interleukin-5 receptor subunit alpha biotech NA drugbank , DGIDB Maintenance[MeSHID:D008283]
Serum[MeSHID:D044967]
Eosinophilia[MeSHID:D004802]
Asthma[MeSHID:D001249]
Lung[MeSHID:D008168]
Cell Differentiation process[MeSHID:D002454]
Continuance of life[MeSHID:D013534]
Phenotype[MeSHID:D010641]
eosinophil[MeSHID:D004804]
Inspiration function[MeSHID:D001239]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Chronic Obstructive Airway Disease[MeSHID:D029424]		 222.78 approved,investigational antibody
benralizumab interleukin 5 receptor alpha NA Successful target TTD , DGIDB Maintenance[MeSHID:D008283]
Serum[MeSHID:D044967]
Eosinophilia[MeSHID:D004802]
Asthma[MeSHID:D001249]
Lung[MeSHID:D008168]
Cell Differentiation process[MeSHID:D002454]
Continuance of life[MeSHID:D013534]
Phenotype[MeSHID:D010641]
eosinophil[MeSHID:D004804]
Inspiration function[MeSHID:D001239]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Chronic Obstructive Airway Disease[MeSHID:D029424]		 222.78 approved unknown
benralizumab interleukin 5 receptor alpha NA Successful target TTD , DGIDB Maintenance[MeSHID:D008283]
Serum[MeSHID:D044967]
Eosinophilia[MeSHID:D004802]
Asthma[MeSHID:D001249]
Lung[MeSHID:D008168]
Cell Differentiation process[MeSHID:D002454]
Continuance of life[MeSHID:D013534]
Phenotype[MeSHID:D010641]
eosinophil[MeSHID:D004804]
Inspiration function[MeSHID:D001239]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Chronic Obstructive Airway Disease[MeSHID:D029424]		 222.78 approved inhibitor
benralizumab interleukin 5 receptor alpha NA Successful target TTD , DGIDB Maintenance[MeSHID:D008283]
Serum[MeSHID:D044967]
Eosinophilia[MeSHID:D004802]
Asthma[MeSHID:D001249]
Lung[MeSHID:D008168]
Cell Differentiation process[MeSHID:D002454]
Continuance of life[MeSHID:D013534]
Phenotype[MeSHID:D010641]
eosinophil[MeSHID:D004804]
Inspiration function[MeSHID:D001239]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Chronic Obstructive Airway Disease[MeSHID:D029424]		 222.78 approved antibody
click here to return to the previous page